A phase 2 randomized, double-blind trial tested oxybutynin 2.5 mg BID and 5 mg BID versus placebo for six weeks in men on stable ADT with ≥28 weekly hot flashes. Dose-dependent efficacy was observed, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results